KINE-101A is under clinical development by Kine Sciences and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase I drugs for Rheumatoid Arthritis have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KINE-101A’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KINE-101A overview
KINE-101A is under development for the treatment of rheumatoid arthritis. It is administered through intravenous and subcutaneous routes. It acts by targeting Treg cells. The drug candidate is a derivative of erythroid differentiation regulator 1 (Erdr1) being developed based on Kine Sciences’ technological platform starts from peptide monotherapy and evolves to peptide cocktail therapy combined with functional immunomics and AI.
Kine Sciences overview
Kine Sciences (KS) is a pharmaceutical company that manufacture drugs for cancer, skin diseases, autoimmune disease and cardiovascular disease. The product pipeline includes kine-101, kine-201, kine 301, kine 401, kine 501 and kine 601 along with the sub variants. Its products The company develops drug candidates of ultra-small peptide with private and public funding including the one from Korea Drug Development Fund. It aims to treat the chronic immune diseases such as rheumatoid arthritis, inflammatory bowel diseases, atopic dermatitis, psoriasis, cancer, Alzheimer’s disease, and many rare immune diseases. Kine Sciences is headquartered in Gangnam, Seoul, South Korea.
For a complete picture of KINE-101A’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
